Literature DB >> 21029053

Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale.

R Schennach-Wolff1, M Obermeier, F Seemüller, M Jäger, T Messer, G Laux, H Pfeiffer, D Naber, L G Schmidt, W Gaebel, J Klosterkötter, I Heuser, W Maier, M R Lemke, E Rüther, S Klingberg, M Gastpar, H-J Möller, M Riedel.   

Abstract

OBJECTIVE: To examine depressive symptoms, their course during treatment, and influence on outcome.
METHOD: Weekly Calgary Depression Scale for Schizophrenia ratings were performed in 249 inpatients with schizophrenia. Early response was defined as a 20% reduction in the total score of the Positive and Negative Syndrome Scale for Schizophrenia from admission to week 2, response as a 50% reduction in the total score of the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) from admission to discharge and remission according to the consensus criteria.
RESULTS: Thirty six per cent of the patients were depressed at admission, with 23% of them still being depressed at discharge. Depressed patients scored significantly higher on the PANSS negative and general psychopathology subscore, featured more impairments in subjective well-being (P < 0.0001) and functioning (P < 0.0001). They suffered from more suicidality (P = 0.0021), and had greater insight into their illness (P = 0.0105). No significant differences were found regarding early response, response, and remission.
CONCLUSION: Patients with depressive symptoms should be monitored closely, given the burden of negative symptoms, their impairments in well-being and functioning and the threat of suicidality.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2010        PMID: 21029053     DOI: 10.1111/j.1600-0447.2010.01608.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  9 in total

1.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

2.  Association between depression in chronic phase and future clinical outcome of patients with schizophrenia.

Authors:  Yuto Yamada; Yusuke Yamauchi; Shinji Sakamoto; Masaki Fujiwara; Yuko Okahisa; Soshi Takao; Manabu Takaki; Norihito Yamada
Journal:  Psychopharmacology (Berl)       Date:  2022-02-21       Impact factor: 4.530

3.  Assessment of trait and state aspects of depression in schizophrenia.

Authors:  Joshua Chiappelli; Katie L Nugent; Kavita Thangavelu; Katherine Searcy; L Elliot Hong
Journal:  Schizophr Bull       Date:  2013-05-17       Impact factor: 9.306

4.  Impact of depressive symptoms on subjective well-being: the importance of patient-reported outcomes in schizophrenia.

Authors:  Jorge Mauriño; Julio Sanjúan; Josep Maria Haro; Teresa Díez; Javier Ballesteros
Journal:  Patient Prefer Adherence       Date:  2011-09-27       Impact factor: 2.711

5.  Burden of schizophrenia among Japanese patients: a cross-sectional National Health and Wellness Survey.

Authors:  Kenji Baba; Wenjia Guo; Yirong Chen; Tadashi Nosaka; Tadafumi Kato
Journal:  BMC Psychiatry       Date:  2022-06-18       Impact factor: 4.144

6.  Depressive symptoms in first episode psychosis: a one-year follow-up study.

Authors:  Nasrettin Sönmez; Kristin Lie Romm; Ole A Andreasssen; Ingrid Melle; Jan Ivar Røssberg
Journal:  BMC Psychiatry       Date:  2013-04-05       Impact factor: 3.630

7.  Depressive Symptoms during an Acute Schizophrenic Episode: Frequency and Clinical Correlates.

Authors:  Ravi Philip Rajkumar
Journal:  Depress Res Treat       Date:  2015-11-18

8.  Psychometric properties of the self-report version of the Quick Inventory of Depressive Symptoms (QIDS-SR₁₆) questionnaire in patients with schizophrenia.

Authors:  Irene M Lako; Johanna T W Wigman; Rianne M C Klaassen; Cees J Slooff; Katja Taxis; Agna A Bartels-Velthuis
Journal:  BMC Psychiatry       Date:  2014-09-03       Impact factor: 3.630

9.  Depression among Patients with Schizophrenia in Ethiopian Mental Health Hospital: Association with Sociodemographic and Clinical Variables: A Cross-Sectional Study.

Authors:  Mandaras Tariku; Tilahun Ali; Tadesse Misgana; Mohammedamin Hajure; Henock Asfaw
Journal:  Depress Res Treat       Date:  2021-02-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.